- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7
- Interventions
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Radiation · Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 281
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD)
- Interventions
- BLINCYTO (Blinatumomab)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- BK Virus Infection
- Interventions
- Viralym-B
- Biological
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- pTVG-HP with rhGM-CSF
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Pralatrexate Injection
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Novi, Michigan • New York, New York
- Conditions
- Healthy, HIV Infection
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- nelarabine, methotrexate, cytarabine, therapeutic hydrocortisone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Vaccinia, Virus Diseases
- Interventions
- JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy, Skin punch biopsy, Bone marrow aspiration
- Biological · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
- Interventions
- Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Hypersensitivity Pneumonitis
- Interventions
- Bronchoscopy with lavage
- Other
- Lead sponsor
- Nabeel Hamzeh
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Healthy
- Interventions
- Exercise
- Other
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Lawrence, Kansas
- Conditions
- Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Liver Cancer
- Interventions
- YE-NEO-001
- Biological
- Lead sponsor
- NantBioScience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
- Interventions
- PHOX2B PC-CAR T Cells
- Biological
- Lead sponsor
- Stephan Grupp MD PhD
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Eosinophilic Esophagitis Caused by Food (Disorder)
- Interventions
- Assay directed diet change
- Diagnostic Test
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Opioid Withdrawal
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Miami Lakes, Florida • Marlton, New Jersey • New York, New York
- Conditions
- HTLV-I Infection, Tropical Spastic Paraparesis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoma
- Interventions
- Patient-specific dosimetry, conventional dosimetry
- Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
- Interventions
- Alemtuzumab, Itacitinib
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV
- Interventions
- Raltegravir
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Small Intestine Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome
- Interventions
- nelarabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 69 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tregalizumab, Placebo
- Drug
- Lead sponsor
- Biotest
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- Paradise Valley, Arizona • Springfield, Illinois • Lincoln, Nebraska + 5 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Melphalan, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tetanus Toxoid Vaccine
- Drug · Procedure · Biological
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- AMV564 14-Day CIV
- Drug
- Lead sponsor
- Amphivena Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • Tampa, Florida • St Louis, Missouri + 2 more
- Conditions
- Influenza
- Interventions
- Commercial TriValent Split Influenza Virus
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 20 Years to 99 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut